Castle Biosciences received approval from the New York State Department of Health for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy for patients aged 12 and older with moderate-to-severe atopic dermatitis. This test helps clinicians select the most effective treatment by analyzing a patient's disease biology from a skin sample, improving personalized care and potentially reducing ineffective treatment cycles. The approval expands access to this precision medicine tool in New York, supporting better outcomes for millions affected by this chronic skin condition. Castle now holds NY approval for all tests in its dermatology and ophthalmology portfolios, enhancing its diagnostic reach.
FLSmidth & Co. A/S continued its share buy-back program initiated on 18 May 2026, repurchasing 61,000 shares between 3 and 7 August 2026 at prices ranging from DKK 487.45 to DKK 511.77 per share. This brings the total shares bought back under the pro...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of early August 2026, the bank has repurchased shares worth approximately DKK 1.57 billion at an average price of D...
Jyske Bank has continued its share repurchase program initiated in February 2026, acquiring shares valued at approximately DKK 1.57 billion by early August 2026. The program, which runs until January 29, 2027, allows the bank to buy back shares up to...
Quadient has been named among the leading providers in The Forrester Wave™: Accounts Payable Invoice Automation Software, Q2 2026, marking its first inclusion in this key industry evaluation. The recognition highlights Quadient's growing presence and...
Bitcoin ETFs attracted $853.54 million in inflows during the first week of August, marking their strongest weekly performance since April 17. Blackrock's IBIT fund was the main driver, contributing over 80% of the inflows, while Ether ETFs also gaine...
